Skip to main content
TipRanks
Go Ultimate75% OFF

Rentokil Initial (RKLIF) AI Stock Analysis

23 Followers
RKLIF

Rentokil Initial

(Other OTC:RKLIF)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Recurring Route-Based ServicesRecurring contracts and regular onsite visits create predictable revenue, while dense routes can improve technician productivity and support cross-selling. This business model provides a durable base for customer retention, operating leverage, and steadier cash generation over the next several quarters.
Negative Factors
Commercial Customer Execution WeaknessLower conversion and retention can weaken the recurring customer base that supports route density and predictable revenue. Continued losses among smaller commercial accounts would raise the cost of replacing revenue, reduce productivity benefits, and make the planned commercial recovery more execution-dependent.

Rentokil Initial (RKLIF) vs. SPDR S&P 500 ETF (SPY)

-40%-30%-20%-10%0%10%20%30%RKLIF-25.21%SPY+13.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$8.96B
Dividend Yield
3.26%
Average Volume (3M)
6,151
Price to Earnings (P/E)
25.3
Beta (1Y)
0.38
Revenue Growth
3.56%
EPS Growth
44.15%
Country
US
Employees
63,388
Sector
Industrials
Sector Strength
63
Industry
Specialty Business Services

Rentokil Initial Business Overview & Revenue Model

Company Description

Rentokil Initial plc, together with its subsidiaries, provides route-based services in North America, Europe, the United Kingdom, Asia, the Middle East, North Africa, Turkey, and Pacific. The company offers a range of pest control services for rodent...

Rentokil Initial Earnings Call Summary

Earnings Call Date:Jul 30, 2026(Q2-2026)|% Change Since:-33.62%|Next Earnings Date:Oct 17, 2024
Earnings Call SentimentPositive

The call presented solid financial progress — revenue and operating profit growth, strong cash conversion (96%) and reduced leverage (2.4x) — and clear operational achievements (transformation savings, branch rollout, improved residential performance and regional brand momentum). However, there are meaningful near-term challenges: slower commercial performance, a late-Q2 weakness in residential (termite) leads, higher central costs, increased legacy-termite provisions and elevated one-off transformation cash costs. Management has a detailed remediation plan (sales and operational excellence, customer focus, simplification) and expects steady progress with some initiatives potentially taking up to two years. Overall, the positives on profitability, cash generation and early transformation wins outweigh the stated headwinds, but execution risk on commercial recovery and simplification remains material.

Positive Updates

Revenue Growth
Half year revenue increased 4.5% to $3.589 billion with organic revenue growth of 3.6%.

Negative Updates

Commercial Segment Underperformance
Commercial growth lagged overall; although commercial leads grew 8%, conversion and retention declined year-on-year with moderate customer losses in small and midsized accounts (partly due to rationalizing heritage Terminix commercial contracts).

Company Guidance

Management reiterated that full‑year profit is expected in line with market expectations and that the group remains on track for >80% cash conversion (H1 conversion 96%; FCF growth +12.8%), with H1 revenue up 4.5% to $3.589bn (organic +3.6%), operating profit $556m (+6.6%) and an operating margin of 15.5% (+30bps); EPS rose 8.3%. Balance sheet targets include leverage at 2.4x (down 0.4x YoY) now within the 2.0–2.5x target range, net debt down $75m and an interim dividend increase of 8%. The company raised its full‑year cash guidance for one‑off/adjusting items to $110–$120m (H1 cash impact $70m), increased expected cash outflow on the legacy termite provision to $115–$125m, reduced FY M&A spend guidance to $120m, and said central costs (H1 +16.9%) should moderate to low double‑digit growth. Regional detail: North America H1 revenue $2.197bn (+4.2%, organic +3.7%), operating profit $393m (+10.2%) margin 17.9% (+1ppt) (Pest Control margin ~20%, up 1.4% since 2024; residential leads +6%; Business Services +10.6%); transformation delivered $45m gross savings in H1 (net $28m) with ~ $90m annualized run‑rate. International H1 revenue $1.392bn (+5.0%, organic +3.5%), operating profit $266m (+4.3%) margin 19.1%; Q2 international pest organic +5.4% (ex certain businesses +5.8%). Overall, there is no change to the outlook.

Rentokil Initial Risk Analysis

Rentokil Initial disclosed 27 risk factors in its most recent earnings report. Rentokil Initial reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Rentokil Initial Peers Comparison

Overall Rating

UnderperformOutperform
Sector (63)

Financial Indicators

RKLIF against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GB:SRPGB:SRP77OutperformGBP 2.62B16.8417.55%1.80%1.20%221.80%
GB:ITRKGB:ITRK73OutperformGBP 9.13B28.5829.86%2.78%3.94%-8.14%
GB:MTOGB:MTO67NeutralGBP 2.65B32.2315.86%2.16%10.55%-19.05%
Sector *63Neutral$10.79B15.437.44%2.01%2.89%-14.66%
GB:JSGGB:JSG62NeutralGBP 512.36M15.2113.74%3.41%1.73%9.66%
GB:RSTGB:RST55NeutralGBP 404.29M145.731.30%2.37%8.11%-69.68%

* Industrials Sector Average

Performance Comparison

-20%0%20%40%RKLIFGB:ITRKGB:JSGGB:MTOGB:RSTGB:SRPDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
RKLIF and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
RKLIFRentokil Initial3.88-1.18-23.26%
GB:ITRKIntertek Group plc5945.001238.7426.32%
GB:JSGJohnson Service146.8018.0414.01%
GB:MTOMitie Group plc208.2058.0338.64%
GB:RSTRestore plc307.5079.7735.03%
GB:SRPSerco Group plc258.8016.226.69%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.